Literature DB >> 20960546

Surgical therapy for diabesity.

Kervin Arroyo1, Subhash U Kini, John E Harvey, Daniel M Herron.   

Abstract

Type 2 diabetes mellitus affects more than 170 million people worldwide. Because this disease is strongly linked to obesity, the term "diabesity" has been coined to describe the confluence of the 2 disease processes. Bariatric surgery has been performed for many years to achieve sustained weight loss in the morbidly obese population. As a secondary effect, a remarkable improvement in glycemic control is commonly achieved postoperatively. This has led to substantial interest in the use of bariatric procedures to treat type 2 diabetes mellitus. Surgical procedures in common use include the adjustable gastric band, the Roux-en-Y gastric bypass, the biliopancreatic diversion with duodenal switch, and the sleeve gastrectomy. Additionally, several investigational procedures including the ileal interposition and duodenal-jejunal bypass have been proposed as primary interventions for type 2 diabetes mellitus. These operations achieve their metabolic effects through a combination of volume restriction, intestinal bypass, and hormonal changes. As more data become available on the positive effect of bariatric procedures on type 2 diabetes mellitus, the use of such operations may grow. Bariatric surgery may ultimately become a major tool in the long-term treatment of type 2 diabetes mellitus. This manuscript presents an extensive review of the literature supporting these concepts.

Entities:  

Mesh:

Year:  2010        PMID: 20960546     DOI: 10.1002/msj.20209

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  2 in total

1.  Resolution of diabetes after bariatric surgery among predominantly African-American patients: race has no effect in remission of diabetes after bariatric surgery.

Authors:  Mereb Araia; Michael Wood; Joshua Kroll; Abdul Abou-Samra; Berhane Seyoum
Journal:  Obes Surg       Date:  2014-06       Impact factor: 4.129

2.  Loss of intestinal GATA4 prevents diet-induced obesity and promotes insulin sensitivity in mice.

Authors:  Jay V Patankar; Prakash G Chandak; Sascha Obrowsky; Thomas Pfeifer; Clemens Diwoky; Andreas Uellen; Wolfgang Sattler; Rudolf Stollberger; Gerald Hoefler; Akos Heinemann; Michele Battle; Stephen Duncan; Dagmar Kratky; Sanja Levak-Frank
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-21       Impact factor: 4.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.